Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Murman, Daniel
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease	Recruiting	3	1200	Europe, Canada, Japan, US, RoW	Remternetug, LY3372993, Placebo	Eli Lilly and Company	Alzheimer's Disease	04/29	10/30
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease	Terminated	3	1027	Europe, Canada, Japan, US, RoW	Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo	Biogen, Biogen Idec Research Limited	Alzheimer's Disease	08/24	08/24
EIP21-NFD-504, NCT05869669: RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies	Active, not recruiting	2	160	Europe, US	Neflamapimod, VX-745, Placebo	EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc	Dementia With Lewy Bodies	08/24	03/25
NCT03622905: ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease	Completed	N/A	74	Europe, Canada, US	DBS-f On, DBS Off	Functional Neuromodulation Ltd	Alzheimer Disease	02/24	02/24